Company profile
Amphastar Pharmaceuticals, Inc.
NASDAQ: AMPH · Healthcare · Drug Manufacturers - Specialty & Generic
#185 of 1,418 Healthcare companies by revenue39th-percentile growth
EA Score
77B+FH 83DQ 78GM 61SS 75
v0.1 · 65/100 weight · provisional
↑ operating margin, net margin · ↓ revenue growth (YoY), listing tenure
Methodology →Revenue TTM
$720.5M
Rev growth YoY (TTM)
-1.1%
Net income (FY)
$98.1M
Employees
1,976
as of 2026-08-10
Market cap
$916.3M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$719.9M$719.9M2025
Net income$98.1M$98.1M2025
Operating income$140.4M$140.4M2025
Total assets$1.6B$1.6B2025
Liabilities$840.5M$840.5M2025
Equity$788.8M$788.8M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Epinephrine100%
By geography
UNITED STATES95%
France5%
China0%
The read
What is Amphastar Pharmaceuticals, Inc.’s revenue?
Amphastar Pharmaceuticals, Inc. booked $719.9M in FY2025 revenue, contracting 1.7% year over year — slower than 61% of Healthcare companies we track, at a 13.6% net margin.
Peers · Healthcare
Repligen Corporation82B+NeoGenomics, Inc.72BPacira BioSciences, Inc.78B+Supernus Pharmaceuticals, Inc.76B+Sienna Senior Living Inc.75B+Avanos Medical, Inc.73BNeighbors
San Bernardino →Key facts
CEOYongfeng Zhang
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersRancho Cucamonga, CA
ExchangeNASDAQ: AMPH
Employees1,976
IPO date2014-06-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.